Didn't find what you were looking for?

Dynamic device captures CTCs safely, enabling monitoring and metastatic control. Publications June 3, 2025 Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Background Primary tumors are known to shed circulating tumor cells (CTCs), promoting systemic dissemination and increasing the risk of metastasis to distant organs. Approximately 90% of cancer-related deaths are directly associated with metastasis. Several studies in animal models suggest improved overall survival following reduction in the number of CTCs in circulation. In this study, we demonstrate the capture of CTCs using a continuous blood-flow device incorporating three-dimensional glass substrates (3D GS) conjugated with affinity ligands, including anti-epithelial cell adhesion molecule (EpCAM) antibody and transferrin (Tf), in cancer patients. Methods A bi-spiral, plano-horizontal, optically transparent device fabricated from biocompatible resin with multiple channels for continuous blood flow was designed using a 3D printer. The circulation device comprised 14 loops capable of holding 17.5 mL of blood and containing 680 glass substrates (2 mm diameter) conjugated with anti-EpCAM antibody and transferrin. The system was mechanized for functional circulation using three pumps. Pyrogenicity resulting from blood passage through the device was evaluated in three New Zealand White rabbits according to ISO:10993-11 guidelines for systemic toxicity assessment. Additionally, 27 blood samples from patients with early- and late-stage cancers across nine cancer types, including colorectal, lung, breast, and ovarian cancers, were processed using the OncoDialysis assay. The cohort consisted of 48.15% male and 51.85% female patients. CTCs were captured using five glass substrates from 1.5–5 mL of blood and validated using CK18 and CD45 markers through fluorescence microscopy. Samples were also analyzed using the Drug Controller, India–approved OncoDiscover technology for comparative evaluation. Results No hemolysis was observed as a result of the device. Continuous circulation of up to 5 mL of blood successfully demonstrated CTC capture within the flow system. All rabbits remained healthy during testing, and none exhibited an individual temperature increase of 0.5°C or more compared with controls, indicating no systemic toxicity. The OncoDialysis assay detected CTCs in 48.15% of patients (n = 13/27), yielding a total of 14 CTCs (12 single CTCs and 2 clusters), with a mean CTC distribution of 0.51 per 1–5 mL of blood. The OncoDiscover platform isolated 23 CTCs (18 single CTCs and 5 clusters), with a mean CTC distribution of 0.8. A concurrence rate of 74.07% was observed between the two platforms. In 40.74% of cases (n = 11/27), CTCs were detected by both systems. Conclusions We developed a dynamic in vitro blood circulation device with demonstrated safety in animal studies, capable of selectively capturing circulating tumor cells from patient blood. Reduction of CTC burden may hold significant therapeutic potential in limiting metastatic spread and improving overall survival in epithelial-origin cancers, both in treated and untreated settings. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Magnetically activated nanocellulose enables efficient CTC capture in head & neck cancer. Publications September 20, 2023 Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. In this report, the relative efficiency of cellulose nanocrystals (CNCs) and nanofibers (CNFs) to capture circulating tumor cells (CTCs) from the blood samples of head and neck cancer (HNC) patients was evaluated. Detection and enumeration of CTCs are critical for monitoring cancer progression. Both types of nanostructured cellulose were chemically modified with epithelial cell adhesion molecule (EpCAM) antibody and iron oxide nanoparticles. The EpCAM antibody facilitated the engagement of CTCs, promoting their entrapment within the cellulose cage structure. Iron oxide nanoparticles, on the other hand, rendered the cages magnetically activatable, enabling the capture and separation of entrapped CTCs using a magnet. The efficiency of the network structures was demonstrated using blood samples from head and neck cancer patients. It was observed that the degree of chemical functionalization of hydroxyl groups within the CNCs or CNFs with anti-EpCAM determined the efficiency of the system’s interaction with CTCs. Furthermore, the results indicated that the inflexible scaffolds of nanocrystals interacted more efficiently with CTCs than the fibrous CNF scaffolds. Network structures derived from CNCs demonstrated comparable CTC-capturing efficiency to the commercial standard, OncoDiscover®. The findings of this work provide chemical design principles for cellulosic materials intended to construct affordable platforms for monitoring cancer progression in real time. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 profiling across cancers supports monitoring, recurrence detection, and MRD. Publications June 3, 2025 Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Background India presents a diverse genetic pool with varying cancer incidence patterns. Common cancers in the Indian population include head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers. Understanding the distribution of circulating tumor cells (CTCs) across these cancers may help account for cellular minimal residual disease (MRD) and early recurrence in solid tumors. Surgery with curative intent can be further evaluated for residual disease using dual biomarkers such as ctDNA and CTCs. Methods In this retrospective analysis, peripheral blood samples from 5,935 patients across various cancer types—including head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers—were evaluated for the presence of CTCs, with and without PD-L1 overexpression and CTC clusters. CTCs were detected using the OncoDiscover platform approved by CDSCO in 1.5 mL of peripheral blood. The platform utilizes a multifunctional magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibodies. CTCs were confirmed as EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ cells. PD-L1 expression on CTCs was analyzed using linear fluorescence intensity gradients acquired through an automated Zeiss microscope. Additionally, a computational model was developed to evaluate CTC frequency, mean distribution, regression analysis, and normal probability plots to assess predictability across cancer types, age groups, stages, and genders. Results The study included 5,935 patient blood samples, comprising 90.07% baseline and 9.92% follow-up samples. CTC counts ranged from 1 to 10 per 1.5 mL of blood, with a mean value of 1.12. Among the patients, 69.87% (n = 2,854) demonstrated PD-L1 expression on their CTCs, with a mean value of 0.99. The 51–60-year age group exhibited the highest proportion of both total CTCs (19.16%, n = 1,137) and PD-L1–positive CTCs (19.71%, n = 805). Most CTC clusters were identified in breast, colorectal, and endometrial cancers. Pancreatic cancer patients showed the highest mean CTC count (1.4), whereas laryngeal cancer samples had the lowest mean count (0.78). The computational model indicated that the 51–60-year age group had the highest impact on cancer prevalence and mean CTC distribution. The model also demonstrated a strong correlation between blood-based outcomes and normal probability scores. Conclusions Higher CTC counts were strongly associated with advanced disease stages, particularly in cancers prone to hematogenous spread, such as breast, lung, and prostate cancers. Incorporating CTC profiling from baseline into diagnostic and surveillance strategies may enhance personalized cancer management. The presence of CTCs in disease-free survival (DFS) settings suggests potential links to poor therapeutic response, disease progression, and minimal residual disease. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC-based PD-L1 and EGFR detection supports targeted therapy in lung cancer. Publications October 24, 2023 ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. Background: Targeted molecular therapy and immunotherapy have revolutionized the treatment of advanced lung cancer (ALC). Although therapeutically significant, the outcome of immune checkpoint inhibitors (ICI) or tyrosine kinase inhibitors (TKI) depends on the presence of their respective targets in tumor cells. Evaluating targets based on solid tissue biopsy may often be misleading, particularly in progressive patients despite therapy administration. Additionally, tissue biopsy provides a static signature of target protein expression from an evolving tumor. The unmet need for dynamic detection and monitoring of actionable targets could be addressed by circulating tumor cells (CTCs). Here, we report on the utility of CTCs to detect actionable targets in advanced lung cancer (ALC) patients. Methods: We retrospectively analyzed 193 ALC patients for programmed death-ligand 1 (PD-L1) and EGFR expression on CTCs. CTCs were isolated using the Drug Controller General of India-approved OncoDiscover technology based on immunomagnetic targeting using anti-EpCAM antibodies and immunostaining with anti-EGFR and PD-L1 antibodies. CTCs were detected based on the expression of cytokeratins (CKs), absence of CD45, and prominent DAPI-stained nuclei. The presence or absence of EGFR and PD-L1 was determined using automated immunofluorescence microscopy. Results: Among the evaluated cohort, 67% of patients showed the presence of CTCs with a mean value of 4.2 (range: 1 to 62; SD = 10.65). The absence of CTCs in the remaining 33% of patients could be attributed to therapy response in clinically stable disease. Among all patients showing the presence of CTCs, 66% showed detectable expression of PD-L1, while 42% showed strong expression of EGFR. The presence of PD-L1 demonstrated a significant association with CTCs. Similarly, the expression of EGFR among detected CTCs showed high significance compared to reported tissue biopsy data in the literature. Conclusions: Detection of therapeutic targets on CTCs obtained from advanced lung cancer patients strongly indicates that these patients may qualify for anti-EGFR and PD-L1 targeted therapies. Systematic studies with larger sample sizes are required to further strengthen liquid biopsy–based detection of actionable targets. This approach could significantly benefit advanced lung cancer patients showing progressive disease despite chemotherapy or radiotherapy. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Innovations at ASCO Annual Meeting 2026 Publications March 17, 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Abstract Background Tumor thrombus (TT) refers to the direct extension of tumor cells into a blood vessel and is often detected incidentally. It is commonly observed in renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and Wilms tumor. The presence of TT significantly worsens prognosis and alters disease staging. TT is frequently located in vessels such as the renal vein, inferior vena cava, and portal vein, requiring multidisciplinary evaluation due to its aggressive nature and risk of obstruction or embolization. Diagnostic differentiation between tumor thrombus and a “bland” thrombus (blood clot) typically relies on imaging techniques such as CT or MRI. In this study, we evaluated the association and potential role of circulating tumor cells (CTCs) expressing immune-relevant markers, such as PD-L1, in patients with tumor thrombus. The presence of CTCs originating from TT margins may help refine risk stratification and therapeutic decision-making. Methods In this observational study, 12 patients aged 51–80 years with confirmed tumor thrombus were analyzed. The cohort included patients with hepatocellular carcinoma (HCC, n = 4), pancreatic cancer (n = 3), liver cancer (n = 3), renal cell carcinoma (RCC, n = 1), and gallbladder cancer (GB, n = 1). Blood samples were analyzed for the presence of CTCs with PD-L1 expression at baseline, and three patients also had follow-up samples. Samples were processed using the CDSCO-approved OncoDiscover CTC enrichment technology. CTCs were identified using an automated Zeiss microscope based on EpCAM⁺, CK18⁺, DAPI⁺, CD45⁻, and PD-L1⁺ markers. Results A total of 16 CTCs were detected in 10 patients (83.33%) from 1.5 mL blood samples, with counts ranging from 1 to 6 CTCs per patient. At baseline, patients with HCC, pancreatic, RCC, gallbladder, and other cancers showed the presence of PD-L1–expressing CTCs. Follow-up samples revealed persistent CTC positivity, although the number of PD-L1–positive CTCs decreased. The mean CTC distribution was 1.33 for CK18-expressing CTCs. PD-L1–positive CTCs were detected in a substantial subset, with a mean distribution of 0.67 (9 CTCs among 12 patients), indicating immune-evasive potential. CTC clusters were rare and detected in only one HCC patient but persisted during follow-up. Both male and female patients demonstrated comparable CTC positivity. Conclusion The presence of CTCs in peripheral blood highlights active tumor cell dissemination from tumor thrombus margins. Although CTC clusters were infrequent, their occurrence may indicate an increased metastatic risk. This study demonstrates, for the first time, the presence of CTCs originating from tumor thrombus margins entering systemic circulation. Further studies are required to better understand their clinical implications. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Self-propelled CNT microrockets enable rapid capture and isolation of CTCs. Publications April 13, 2015 Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. We demonstrated a novel carbon nanotube (CNT)-based microrocket that propels efficiently through the thrust generated by oxygen (O₂) bubbles. These self-propelled microrockets exhibit ultrafast propulsion in aqueous solutions as well as in Dulbecco’s modified Eagle’s medium (DMEM). The microrocket generated a driving force of over 231 and 300 pN in DMEM containing 4% hydrogen peroxide (H₂O₂). The speed and distance traveled by the microrocket can be controlled by adjusting the concentration of H₂O₂. The designed multifunctional microrocket has the ability to (i) rapidly target (~5 minutes) and efficiently capture (~85%) transferrin receptor–positive (TfR⁺) cancer cells from an artificial CTC-like suspension, (ii) magnetically isolate the captured cells from peripheral blood cells, and (iii) enable subsequent high-resolution imaging. We envision that such self-powered micromotors could provide a novel and effective approach for the rapid and efficient extraction of circulating tumor cells (CTCs) from biological fluids, supporting early cancer diagnosis and detection of recurrence. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover Available in India | Dr. Jayant Khandare Expert Insights August 9, 20222 OncoDiscover Available in India | Dr. Jayant Khandare OncoDiscover Available in India | Dr. Jayant Khandare This test is made available and accessible in India. And this is what this simple and completely painless blood test has been clinically validated in a study of thousands of patients with the support of Tata memorial hospital, now being used by many oncologists to monitor their patients so as to give their better treatment options, and to know if the cancer patient is completely disease free. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CK18 variance in CTCs across cancer types necessitates validated enumeration. Publications October 9, 2021 ESMO 2021: Validation of Cytokeratin (CK18) Protein Expression in Epithelial Cell lines and in Circulating Tumor Cells (CTCs) Study shows significant CK18 expression variance across different cancer cell lines and CTCs, highlighting the need for regulated enumeration tools. Background CTCs predict an unfavourable prognosis and outcomes in cancers. Lowering of cytokeratin 18 expression is a hallmark of epithelial mesenchymal transition (EMT). Homogeneity and validation of CK18 expression in cancer cell lines and CTCs originating from distinct solid tumors is indeterminate and may contribute to non-specific counts. We hypothesize that the expression of CK18 in varied cell lines may differ quantitatively, and additionally may exhibit similar trends in CTCs enumerated from different tumor types. Methods CK18 variance in epithelial cell lines (e.g., A549+, MCF-7+, and MEF-) (n=192,269 cells) and CTCs (n=63) of different phenotypes was analyzed and compared. The fluorescence intensity was measured post-immunostaining, using motorized-automated, computer-assisted scanning, and through a customized ImageJ macro tool. The effect of anti-CK18 concentrations (0.06-6 μg/ml) and binding constants (Kb) was measured across all cell lines. CTCs were enumerated from head and neck squamous cell carcinoma (HNSCC) patients' blood samples (CTRI/2018/03/012905) and from clinical samples (e.g., breast, lung, colorectal (CRC), ovarian) using the clinically relevant OncoDiscover platform. Results CK18 mapping revealed diverse fluorescence intensities distribution in three cell lines, as well as in HNSCC, lung, breast, ovarian, and colorectal cancer CTCs (Table). In addition, the protein binding assay showed 8.65 x 10^3 Kb (M^-1) for MCF7 and 7.9 x 10^3 for A549 cells indicating concentration-dependent binding for CK18 expressing proteins on cells and may be varied in CTCs of different cancer types. Compared to the CK- cell line (MEF), the normalized CK18 intensity was higher by 290% and 310%, respectively, in MCF7 (breast) and A549 (lung) cells, demonstrating the variation in CK18 expression. On the other hand, CTCs showed significant diversity in CK18 expression with buccal mucosa revealing the lowest (67%), while CTCs of CRC origin demonstrated the highest expression (320%) (Table). CK18 intensity was represented across the cell lines and on CTCs enumerated from different cancer types. Conclusions Non-regulated CTC enumeration platforms pre-requisite critical validations to eliminate the non-specificity of CTC counts, which are highly imperative to clinical decisions in cancer management. Clinical Trial Identification CTRI/2018/03/012905. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Pune start-up gets US patent for delivering drugs to site-specific organs Press Release March 6, 2023 Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Changes in lifestyle and food habits are leading to many colon related diseases including cancers, he said. Delivery of drugs to colorectal site is most challenging as the dosage forms have to prevent the early release of drug in stomach and intestine, he said. This patent (US Patent No. 11596607) is titled "Polymer based formulation for the release of drugs and bioactives at specific GIT sites". Khandare said the technology composition does not involve cumbersome tablet processing, coating and enteric or other polymers. It also reduces processing cost with increased patient compliance, he added. The start-up completed the bio equivalence study which was approved by Drugs Controller General of India (DCGI) in September 2020, Khandare said. Click the link below to read the full article. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

The POP device effectively removes CTCs from blood to reduce metastatic progression. Publications July 15, 2020 ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival. Background: The presence of circulating tumor cells (CTC) in the vascular system is a tell-tale signature of metastasis in epithelial origin cancers including lung, breast, colorectal and head and neck cancers. Noteworthy, about 90% of cancer deaths are due to the progression of metastasis. Yet, cancer therapy is focussed on inhibiting tumour growth and there is a paucity of options that target metastasis. We demonstrate the POP ‘device’ that removes circulating tumour cells (CTC) from a patient’s blood to reduce the metastatic progression and improve overall survival. Methods: We designed, multi-component glass beads enriched antibody EpCAM conjugate substrates as POP blood fluidic device. We characterized the substrate and accounted for the biocompatibility using whole blood of healthy volunteers. We evaluated, the acute toxicity of substrates using rat (Wistar Albino) whole blood (CPCSEA registration number: 941/PO/Re/S/06/CPCSEA; 31/07/2019) and further studied major histopathological tissues for any toxicity. Finally, we evaluated 06 cancer patients whole blood (1.5 mL) for capturing and for the elimination of CTCs. The captured cells were immuno-stained, and the optimal fluorescence acquisition intensity was critically quantified in accounting CK18 protein overexpression. Results: The multi-component antibody EpCAM based substrate exhibited efficient CTC capture ability with a mean capture efficiency ranging from 40% to 100 % when compared to the OncoDiscover CTC test approved by CDSCO/ drug controller general of India (DCGI). Furthermore, the substrate indicated high biocompatibility primarily exhibited by the absence of haemolysis on whole human blood. Additionally, the preliminary animal experiments in rats showed a 100% survival rate and negligible toxicity to major organs. Conclusions: Removal of circulating tumor cells as a therapeutics is highly implicated in improving the overall survival of epithelial cancer patients. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Cellulose-based transferrin nanocages for CTC enumeration in head & neck cancer. Publications October 10, 2020 Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Herein, we report a hierarchically organized, water-dispersible “nanocage” composed of cellulose nanocrystals (CNCs), magnetically powered by iron oxide (Fe₃O₄) nanoparticles to capture circulating tumor cells (CTCs) from the blood of head and neck cancer (HNC) patients. Capturing CTCs from peripheral blood is extremely challenging due to their low abundance, yet their enumeration is clinically validated in assessing progression-free survival in HNC patients. By engaging multiple hydroxyl groups along the molecular backbone of CNCs, Fe₃O₄ nanoparticles were coordinated onto the CNC scaffold. This structure was further modified through conjugation with the protein transferrin (Tf) to enable targeted capture of CTCs. Owing to the presence of Fe₃O₄ nanoparticles, the nanocages exhibited magnetic properties, allowing CTCs to be captured under the influence of a magnetic field. Tf–CNC-based nanocages were evaluated using blood samples from HNC patients and their CTC capturing efficiency was compared with the clinically relevant Oncoviu platform. The results demonstrated that CNC-derived nanocages efficiently isolated CTCs from patient blood, achieving approximately 85% capture efficiency relative to the standard platform. The capture efficiency was found to vary depending on the concentration of transferrin and Fe₃O₄ nanoparticles immobilized onto the CNC scaffold. We envision that the Tf–CNC platform holds significant potential in liquid biopsy applications for the isolation and enumeration of CTCs, enabling early detection of metastasis in cancer. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore our innovative patents. Discover the power of innovation and precision in our groundbreaking patent solutions. Patents & Certifications Proof of Precision. Power of Innovation. We are committed to utmost scientific rigour. Every product at Actorius Innovations and Research undergoes intense design and development. Our products are patented worldwide. We follow the most stringent quality norms (ISO13485) and applicable regulatory requirements for medical devices (rules 2017) October 20, 2025 Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Read More February 13, 2023 Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Read More April 22, 2021 Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Read More February 26, 2020 Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Read More First Prev 1 Page 1 Next Last